The U.S. District Court for the District of Delaware has denied CareDx’s motion for summary judgment on two patents in the patent infringement lawsuit filed by Natera against CareDx.
The lawsuit, filed last year, accuses CareDx of infringing on two patents that cover DNA amplification technology in Natera’s Panorama noninvasive prenatal testing assay. The trial is scheduled to start on January 22, 2024.
The two companies have filed multiple lawsuits against each other in recent years. In 2021, CareDx filed a patent infringement suit against Natera involving three patents in the same court as the present case; the court ruled that the patents licensed by CareDx from Stanford University were invalid due to patent-ineligible subject matter. The U.S. Court of Appeals for the Federal Circuit denied CareDx’s appeal; the U.S. Supreme Court subsequently declined to review the decision when CareDx escalated the case.
A 2022 case brought by CareDx against Natera for false advertisement involving Natera’s Prospera transplant test resulted in a jury award to CareDx of $45 million; the ruling was later amended such that CareDx was not entitled to damages. However, CareDx received an injunction later that year prohibiting Natera from falsely advertising and overstating the performance of the Prospera test.
